Kyntra Bio Inc (KYNB) – What Are Brokerages Saying About This Stock?

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $36.80.

A number of equities research analysts recently issued reports on the stock. Lake Street Capital started coverage on shares of Kyntra Bio in a research note on Thursday, September 17th. They issued a “buy” rating and a $41.00 price target on the stock. Maxim Group began coverage on shares of Kyntra Bio in a report on Tuesday. They issued a “buy” rating and a $35.00 price target for the company. HC Wainwright restated a “buy” rating and set a $43.00 price objective on shares of Kyntra Bio in a research report on Tuesday, September 1st. Weiss Ratings cut shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday. Finally, Oppenheimer started coverage on shares of Kyntra Bio in a report on Monday, July 6th. They set an “outperform” rating and a $35.00 price objective on the stock.

Kyntra Bio Price Performance

Shares of KYNB stock opened at $5.87 on Wednesday. The company has a market cap of $23.77 million, a price-to-earnings ratio of 0.13 and a beta of 1.05. The stock has a 50 day simple moving average of $7.26 and a 200-day simple moving average of $7.12. Kyntra Bio has a 1-year low of $5.62 and a 1-year high of $11.65.

Institutional Trading of Kyntra Bio

An institutional investor recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio as of its most recent SEC filing. 72.71% of the stock is currently owned by institutional investors.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.